No Abstract BioWorld International CorrespondentMovetis NV is testing the mettle of European life sciences investors with the sector's first sizeable initial public offering since the first quarter of 2008.With a European product launch imminent, the company offers a far less risky proposition than most, however.

LONDON - The flood of new money into European biotechs continued as Oxagen Ltd. announced the completion of a £16 million (US$26.4 million) third-round funding, with new investor Novartis Venture Funds leading the round. (BioWorld International)

No Abstract BioWorld International CorrespondentCellerix raised €27 million (US$40.6 million) in the first closing of a new investment round, which it aims to expand to €35 million by year-end.